MannKind Corporation (MNKD)
$
4.12
+0.05 (1.21%)
Key metrics
Financial statements
Free cash flow per share
0.0715
Market cap
1.3 Billion
Price to sales ratio
4.2588
Debt to equity
-0.8061
Current ratio
2.3611
Income quality
0.9739
Average inventory
28.4 Million
ROE
-0.2102
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
MannKind Corporation, a biopharmaceutical firm incorporated in 1991 and headquartered in Westlake Village, California, focuses on the development and commercialization of inhaled therapeutic products aimed at treating endocrine and orphan lung diseases in the United States. Its flagship product, Afrezza, is an inhaled insulin designed to enhance glycemic control in adults with diabetes, reflecting the company's commitment to innovative diabetes care. Additionally, MannKind promotes Thyquidity to both adult and pediatric endocrinologists, as well as other healthcare providers, for managing hypothyroidism, showcasing its diverse therapeutic portfolio. The financial aspects of the company reveal that the income before tax ratio is 0.11 reflecting the pre-tax margin achieved through its operations. Furthermore, the net total of other income and expenses is -$42,069,000.00 which showcases the impact of non-core financial activities. The company incurred an interest expense of $37,981,000.00 underscoring its debt servicing obligations. Notably, the EBITDA is $77,467,000.00 which serves as a key indicator of the company’s operational profitability, while the operating income ratio is 0.25 indicating the company’s operational profitability margin and efficiency in generating earnings. In terms of investment potential, the stock is affordable at $4.12 making it suitable for budget-conscious investors seeking entry into the market. With a high average trading volume of 1,988,769.00 the stock indicates strong liquidity, facilitating easier buying and selling for investors. MannKind Corporation holds a market capitalization of $1,252,203,960.00 classifying it as a small-cap player within the biopharmaceutical sector. It is regarded as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving advancements in inhaled therapeutics. Moreover, it belongs to the Healthcare sector, which is known for fostering innovation and growth, enhancing the company's role in improving patient outcomes through its specialized therapeutic approaches.
Is MannKind Corporation (MNKD) a good investment?
Investing in MannKind Corporation (MNKD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is MannKind Corporation (MNKD)'s stock forecast?
Analysts predict MannKind Corporation stock to fluctuate between $4.05 (low) and $7.63 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is MannKind Corporation's market capitalization?
As of 2025-05-29, MannKind Corporation's market cap is $1,252,203,960, based on 303,933,000 outstanding shares.
How does MannKind Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., MannKind Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy MannKind Corporation (MNKD) stock?
To buy MannKind Corporation (MNKD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MNKD. Place an order (Market, Limit, etc.).
What is the best time to invest in MannKind Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has MannKind Corporation stock ever split?
MannKind Corporation's last stock split was 1:5 on 2017-03-03.
How did MannKind Corporation perform in the last earnings report?
Revenue: $285,504,000 | EPS: $0.10 | Growth: -323.71%.
Where can I find MannKind Corporation's investor relations reports?
Visit https://www.mannkindcorp.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for MannKind Corporation?
You can explore historical data from here
What is the all-time high and low for MannKind Corporation stock?
All-time high: $7.63 (2024-11-06) | All-time low: $2.49 (2022-02-28).
What are the key trends affecting MannKind Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit.
seekingalpha.com
MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, supporting its focused pipeline and future growth opportunities. MannKind's Technosphere technology holds promise for additional partnerships beyond United Therapeutics, enhancing long-term potential.
seekingalpha.com
MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Conference Call Participants Olivia Brayer – Cantor Anish Nikhanj – RBC Andreas Argyrides – Oppenheimer & Co. Yun Zhong – Wedbush Anthony Petrone – Mizuho Operator Good morning, and welcome to the MannKind Corporation First Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on May 08, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
globenewswire.com
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v.
globenewswire.com
Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif.
globenewswire.com
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
seekingalpha.com
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & Renshaw Yun Song - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
zacks.com
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
See all news
